ONX-0914 TFA

• CAT Number: I045409
• Molecular Formula: C33H41F3N4O9
• Molecular Weight: 694.70
• Purity: ≥95%
• Synonyms: (2S)-3-(4-methoxyphenyl)-N-[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide;2,2,2-trifluoroacetic acid
• InChI: InChI=1S/C31H40N4O7.C2HF3O2/c1-21(32-27(36)19-35-13-15-41-16-14-35)29(38)34-26(18-23-9-11-24(40-3)12-10-23)30(39)33-25(28(37)31(2)20-42-31)17-22-7-5-4-6-8-22;3-2(4,5)1(6)7/h4-12,21,25-26H,13-20H2,1-3H3,(H,32,36)(H,33,39)(H,34,38);(H,6,7)/t21-,25-,26-,31+;/m0./s1
• InChIKey: BWAZEOKWIYGOGB-VNFRHJSSSA-N
• SMILES: CC(C(=O)NC(CC1=CC=C(C=C1)OC)C(=O)NC(CC2=CC=CC=C2)C(=O)C3(CO3)C)NC(=O)CN4CCOCC4.C(=O)(C(F)(F)F)O

ONX-0914 TFA (Cat No.: I045409) is the trifluoroacetic acid salt form of ONX-0914, a selective, irreversible inhibitor of the immunoproteasome’s LMP7 (β5i) subunit. By covalently binding to the active site threonine, it blocks chymotrypsin-like activity, modulating immune cell function and cytokine production. Originally developed for autoimmune and inflammatory disorders, ONX-0914 TFA has shown potential in preclinical models of rheumatoid arthritis, lupus, and multiple myeloma. Its selectivity allows targeted modulation of immune responses while sparing constitutive proteasome activity, making it a valuable tool in immunology research.

Reference

[1]. Muchamuel T, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis [published correction appears in Nat Med. 2009 Nov;15(11):1333]. Nat Med. 2009;15(7):781-787.
[Content Brief]

[2]. Rožman K, et al. Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome. Molecules. 2020;25(6):1305. Published 2020 Mar 12.
[Content Brief]

[3]. Lin J, et al. PR-957, a selective immunoproteasome inhibitor, reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1. Biochem Pharmacol. 2018;156:511-523.
[Content Brief]